YourEncore Insights - Life Sciences

Improving R&D Productivity with Activity Based Costing

Posted by Lawrence Maisel on 10/24/17 11:20 AM

Today’s prevailing wisdom is that R&D costs are on the rise while ROI on those investments are down. The Tufts Center for the Study of Drug Development puts the total costs of new drug around $2.7B (in 2017 dollars) while another study1 highlights the fact that the ROI on R&D investment has fallen to 3.7% which is the lowest figure in the past six years. As such, the pharmaceutical industry’s focus on improving productivity is a critical issue.

Read More

Topics: Pharmaceutical Industry, Productivity, R&D